Understanding Neurotrophic keratitis
The defining problem is reduced or absent corneal sensation with impaired surface maintenance. Herpes-related disease, diabetes, eye or nerve surgery, trauma and several congenital disorders can damage the relevant trigeminal nerve pathway. The same diagnosis can therefore have quite different causes. [1] [2]
Severity ranges from early surface changes to a persistent epithelial defect and deeper ulceration. A closed surface, restored sensation and useful vision are related but different outcomes; an eye may still have scar-related visual difficulty after a wound heals. [2] [4]
One condition. Different experiences.
Explore different selected symptom features, then read how they may vary. These examples are not stages or a clinical test.
Original VisualSim schematic illustrations, informed by the cited clinical descriptions. These are not study figures, patient recordings or validated severity levels.
Blur or irregular detail
An uneven surface, ulcer or scar can reduce clarity. The amount of blur does not reliably describe the depth of injury. [1]
Surprisingly little discomfort
Some people notice few symptoms despite important damage. Others have tearing, redness or pain, so the condition is not defined by complete absence of pain. [4]
Children may not describe a change
Congenital or inherited causes are important in childhood. Surface opacity can also interfere with visual development and cause amblyopia, making pediatric assessment different from adult care. [5]
Why sensation and healing belong together
Original educational schematic; not a staging tool or a prediction for an individual eye. [1] [2]
Original VisualSim teaching diagram · © VisualSim. Clinical basis in linked sources; not a published study figure. Image provenance.- Nerve dysfunction
Corneal sensory input and maintenance signals are reduced.
- Surface vulnerability
Protective tears, blinking and epithelial repair may be impaired.
- Separate outcomes
The clinician tracks wound closure, tissue depth, sensation and vision separately.
What is happening—and what remains uncertain
Corneal sensory nerves contribute to protective blinking, tears and the chemical signals that maintain epithelial cells. Nerve dysfunction can weaken these protective and repair processes rather than merely making the eye feel numb. [1]
A persistent epithelial gap leaves deeper tissue vulnerable. Infection, inflammation, eyelid exposure and medication toxicity can coexist, so identifying a nerve problem does not end the search for other contributors. [2] [6]
What can look similar?
Dry eye is not the whole explanation
Dry eye and neurotrophic disease can coexist. Sensation testing and examination of a nonhealing defect help distinguish nerve-related failure from an ordinary dry-eye symptom description. [2]
A painful recurrent erosion has a different pattern
Recurrent corneal erosion often causes episodes related to poor epithelial adhesion. A persistent, relatively insensitive wound raises different questions and needs its own examination. [1] [6]
Infection must still be considered
A corneal ulcer is not automatically sterile because the eye is neurotrophic. Infectious keratitis and inflammatory disease can require a different treatment plan. [1]
Similar-looking symptoms can have different causes. A matching picture cannot establish a diagnosis.
What an assessment may involve
- History and both-eye examinationThe clinician reviews infection, operations, systemic disease, drops and contact-lens use, then examines the lids and ocular surface. In children the developmental and family history may change the investigation. [2] [5]
- Sensation and surface measurementsClinical sensation testing is combined with slit-lamp staining and measurement of any epithelial defect or thinning. This is an examination, not a home test with cotton or another object. [2]
- Cause, depth and complicationsThe team determines whether additional imaging, microbiology or systemic evaluation is needed. Repeated measurements are useful because symptoms alone may understate progression. [6]
What may help—and what is still being studied
Protect and support the surface
Treatment may combine prescribed lubrication, management of exposure and the underlying cause, and a review of potentially toxic drops. Do not stop essential eye medicines yourself; alternatives and monitoring need an agreed plan. [2] [6]
Targeted treatment has a specific evidence base
Cenegermin is a nerve-growth-factor medicine. The opened US label establishes use for neurotrophic keratitis and describes pediatric support from adult trials plus safety data from age two; this is not a worldwide eligibility statement. Eye pain and inflammation are among reported adverse reactions. [3] [7]
Procedures are selected for the problem
A specialist may consider supervised therapeutic lenses, amniotic membrane, partial lid closure or other protective surgery. Corneal neurotization aims to restore sensory supply in selected cases; suitability, time to benefit and residual scarring need separate discussion. [1] [5] [6]
What this can mean for daily life
Use the agreed schedule
Ask for a clear written plan, handling instructions and who to call between appointments. Do not use comfort alone to decide when treatment or follow-up is no longer needed. [2] [6]
Avoid unmonitored surface treatments
Therapeutic contact lenses and blood-derived drops require professional preparation, fitting and surveillance. Ordinary contact lenses or leftover drops are not equivalent substitutes. [1] [6]
Make visual tasks accessible
If blur persists, larger print, adjustable screen magnification and help with visually demanding tasks can reduce the burden while treatment continues. Ask whether a formal low-vision assessment would help. [6]
Plan pediatric follow-up
Families may need help coordinating surface care, glasses and assessment for amblyopia. A comfortable child may still need regular surveillance of an insensitive cornea. [5]
Bring a clearer description to your appointment
Choose the questions you want to discuss. These choices stay in this page’s memory.
Research, with the context left in
Selected studies and guidance, with their populations and limitations. These are curated educational summaries, not a complete systematic review or a formal evidence rating.
NGF0214 pivotal cenegermin trial
At eight weeks the strict zero-staining endpoint was reached by 15 of 23 evaluated treated eyes versus 4 of 24 vehicle-treated eyes. [3]
Limits and applicability: Small study of established defects; wound closure is not proof of normalized sensation, everyday visual function or permanent cure. Trial and regulatory summaries report different healing definitions.
Medical and surgical interventions for neurotrophic keratopathy
Recombinant nerve growth factor may support wound healing; comparative evidence for vision, sensation and several other interventions remained uncertain. [4]
Limits and applicability: The review judged much evidence low or very low certainty because of small samples, inconsistent outcomes and study limitations. It includes the pivotal trials rather than providing an independent new treated cohort.
Expert consensus on identification, diagnosis and treatment
Supported sensation testing with surface examination and a stage- and cause-sensitive approach to care. [2]
Limits and applicability: Expert agreement supports clinical organization but is not a comparative treatment trial; the authors call for validation with clinical data.
Questions researchers still need to answer
- Which treatments give durable improvements in sensation and daily visual function, beyond closing the epithelial defect?
- Which children or adults benefit most from neurotization, and how should its timing be compared with medical treatment?
Trusted places to go next
Selected clinical references, research, practical support and ways to connect. Official pages checked 24 October 2026; each entry explains its scope and region.
Cochrane: neurotrophic keratopathy treatments
Plain-language explanation of what comparative treatment studies do and do not establish; not an individual treatment plan.
Neurotrophic keratopathy: diagnosis and management update
Detailed clinical review for discussing tests and treatment categories with a corneal specialist; includes clinical photographs, which may be uncomfortable to view.
DailyMed: US cenegermin prescribing information
Opened February 2025 revised label, including adverse effects and handling information. Local prescribing and availability can differ.
RNIB community connection and wellbeing
Broader peer connection for people affected by persistent sight difficulties and their families; not a condition-specific group or medical advice. Check each service’s geographic eligibility.
Connections listed by the organization.
Questions you may still have
Can serious damage happen without pain?
Yes. Reduced sensation can mask a worsening wound. Follow the eye team’s monitoring and return plan rather than waiting for discomfort. [2] [6]
Is this simply severe dry eye?
No. Surface dryness can coexist, but corneal nerve dysfunction and impaired healing are central to this diagnosis. [1]
Sources, image credits and review status
Compiled by VisualSim from clinical references and published research. Sources checked 24 October 2026. Independent clinical review has not been recorded; no named clinical reviewer or clinical validation is claimed. Research evidence and its limitations are linked below.
- Font and Cortina: Neurotrophic keratopathy—update in diagnosis and management (2025; review).
Opened the relevant source text; educational material, not independent clinical review.
Checked 2026-10-24 · Full text checked - Dana and colleagues: Expert consensus on identification, diagnosis and treatment of neurotrophic keratopathy (2021; guideline).
Opened the relevant source text; educational material, not independent clinical review.
Checked 2026-10-24 · Full text checked - Pflugfelder and colleagues: Topical recombinant human nerve growth factor—pivotal trial (2020; trial).
Original indexed abstract verified; direct publisher fetch returned403. Strict and less restrictive staining outcomes are not interchangeable.
Checked 2026-10-24 · Abstract/indexed material checked; complete full-text review not claimed - Kruoch and colleagues: Medical and surgical interventions for neurotrophic keratopathy (2025; systematic review).
Opened publisher plain-language and abstract summary; seven studies/494 participants, search January 2025.
Checked 2026-10-24 · Public page checked - Jiang, Ashton and Larkin: Neurotrophic keratopathy in childhood (2026; review).
Opened the relevant source text; educational material, not independent clinical review.
Checked 2026-10-24 · Full text checked - StatPearls: Neurotrophic keratitis (2025; review).
Opened the relevant source text; educational material, not independent clinical review.
Checked 2026-10-24 · Full text checked - DailyMed: Oxervate US prescribing information, revision February 2025 (2025; institution).
Opened the relevant source text; educational material, not independent clinical review.
Checked 2026-10-24 · Public page checked
The simulator helps people communicate an experience. It cannot diagnose a condition, measure a visual field, or establish that someone is safe to drive.